Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorVieites, B.
dc.contributor.authorLópez‑García, M. Á.
dc.contributor.authorMartín‑Salvago, M. D.
dc.contributor.authorRamirez‑Tortosa, C. L.
dc.contributor.authorRezola, R.
dc.contributor.authorSancho, M.
dc.contributor.authorPeg Camara, Vicente
dc.date.accessioned2021-07-09T06:44:32Z
dc.date.available2021-07-09T06:44:32Z
dc.date.issued2021-07
dc.identifier.citationVieites B, López-García MÁ, Martín-Salvago MD, Ramirez-Tortosa CL, Rezola R, Sancho M, et al. Predictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification: the NEOVATTL study. Clin Transl Oncol. 2021 Jul;23(7):1377–1385.
dc.identifier.issn1699-048X
dc.identifier.urihttp://hdl.handle.net/11351/6138
dc.descriptionBreast cancer; Sentinel lymph node; Total tumor load
dc.description.abstractObjective To evaluate the predictive and prognostic value of total tumor load (TTL) in sentinel lymph nodes (SLNs) in patients with infiltrating breast cancer after neoadjuvant systemic therapy (NST). Methods This retrospective multicenter study used data from a Spanish Sentinel Lymph Node database. Patients underwent intraoperative SLN biopsy after NST. TTL was determined from whole nodes using a one-step nucleic acid amplification (OSNA) assay and defined as the total sum of CK19 mRNA copies in all positive SLNs. Cox-regression models identified independent predictive variables, which were incorporated into a nomogram to predict axillary non-SLN metastasis, and identified prognostic variables for incorporation into a disease-free survival (DFS) prognostic score. Results A total of 314 patients were included; most had no lymph node involvement prior to NST (cN0; 75.0% of patients). Most received chemotherapy with or without biologic therapy (91.7%), and 81 patients had a pathologic complete response. TTL was predictive of non-SLN involvement (area under the concentration curve = 0.87), and at a cut-off of 15,000 copies/µL had a negative predictive value of 90.5%. Nomogram parameters included log (TTL + 1), maximum tumor diameter and study-defined NST response. TTL was prognostic of disease recurrence and DFS at a cut-off of 25,000 copies/µL. After a 5-year follow-up, DFS was higher in patients with ≤ 25,000 copies/µL than those with > 25,000 (89.9% vs. 70.0%; p = 0.0017). Conclusions TTL > 15,000 mRNA copies/µL was predictive of non-SLN involvement and TTL > 25,000 mRNA copies/µL was associated with a higher risk of disease recurrence in breast cancer patients who had received NST.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesClinical and Translational Oncology;23(7)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectNodes limfàtics - Biòpsia
dc.subjectMama - Càncer - Tractament
dc.subjectPrognosi
dc.subject.meshSentinel Lymph Node Biopsy
dc.subject.meshTreatment Outcome
dc.subject.meshBreast Neoplasms
dc.subject.mesh/therapy
dc.titlePredictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification: the NEOVATTL study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s12094-020-02530-4
dc.subject.decsbiopsia del ganglio linfático centinela
dc.subject.decsresultado del tratamiento
dc.subject.decsneoplasias de la mama
dc.subject.decs/terapia
dc.relation.publishversionhttps://link.springer.com/article/10.1007/s12094-020-02530-4
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Vieites B] Department of Pathology, Hospital Universitario Virgen del Rocío, Sevilla, Spain. [López-García MÁ] Department of Pathology, Hospital Universitario Virgen del Rocío, Sevilla, Spain. CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Instituto de Salud Carlos III, Madrid, Spain. [Martín-Salvago MD, Ramirez-Tortosa CL] Department of Pathology, Hospital Universitario Materno-Infantil, Jaén, Spain. [Rezola R] Department of Pathology, Onkologikoa Kutxa Fundazioa, Donostia, Spain. [Sancho M] Department of Pathology, Hospital Universitario de Salamanca, Salamanca, Spain. [Peg V] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Instituto de Salud Carlos III, Madrid, Spain
dc.identifier.pmid33517542
dc.identifier.wos:000613168400002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record